Global Pharma Revenue Will Reach



\$1,220,000,000,000+

Between now and 2020, The global pharma industry will have a rare opportunity to provide a growing record number of new drugs to growing population that is able to afford more specialized medicines.



Strong industry's late-stage pipeline of 2,240 drugs and the growing trend of single-company, multi-product launches over last 27 months is expected to translate into an unprecedented average of 45 launches per year.



POPULATION


3.5% global population growth will result in the first time in human history when people over 65 will outnumber children under 5.



PRICE


Complex drugs continue to deliver more value, which is reflected in their average increases by 5.1% for specialized products and 1% for orphan indications.

https://www.pwc.com/gx/en/ceo-agenda/ceosurvey/2017/gx/industries/pharmaceuticals-and-life-sciences.html



Global Launch Excellence

PLAN your next move



International Reference Pricing

Continuously **EXECUTE** flawlessly

PCR volume (each having the potential to cut price by up to 80% in another country)

Increase in volume handled due to ease Average annualized Price Change Requests related metrics for each

\$1 Billion of company Rx revenue. \$243,820

Reduction in time spent 1.3%

Results in **proven** ability to mitigate \$60,000,000 in losses due to **inevitable** price erosion.

Sources: FDA, EFPIA, PhRMA, IMS Midas / Health, IHS, UN DESA, EvaluatePharma, EUnetHTA CuttingEdge, SKP Consulting, WHO, CB Partners, EU Commission on Rx Pricing, WHO